Bijl MJ - Search Results

1

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.

Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH. Lammers LA, et al. Among authors: bijl mj. Br J Cancer. 2010 Sep 7;103(6):765-71. doi: 10.1038/sj.bjc.6605800. Epub 2010 Aug 10. Br J Cancer. 2010. PMID: 20700120 Free PMC article.

2

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.

Bijl MJ, Visser LE, van Schaik RH, Kors JA, Witteman JC, Hofman A, Vulto AG, van Gelder T, Stricker BH. Bijl MJ, et al. Clin Pharmacol Ther. 2009 Jan;85(1):45-50. doi: 10.1038/clpt.2008.172. Epub 2008 Sep 10. Clin Pharmacol Ther. 2009. PMID: 18784654

3

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.

Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BH, van Schaik RH. Bijl MJ, et al. Br J Clin Pharmacol. 2008 Apr;65(4):558-64. doi: 10.1111/j.1365-2125.2007.03052.x. Epub 2007 Dec 7. Br J Clin Pharmacol. 2008. PMID: 18070221 Free PMC article.

4

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.

Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE. Bijl MJ, et al. Breast Cancer Res Treat. 2009 Nov;118(1):125-30. doi: 10.1007/s10549-008-0272-2. Epub 2009 Feb 3. Breast Cancer Res Treat. 2009. PMID: 19189212

5

Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly.

Bijl MJ, Luijendijk HJ, van den Berg JF, Visser LE, van Schaik RH, Hofman A, Vulto AG, van Gelder T, Tiemeier H, Stricker BH. Bijl MJ, et al. Pharmacogenomics. 2009 Apr;10(4):541-7. doi: 10.2217/pgs.09.9. Pharmacogenomics. 2009. PMID: 19374513

6

Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants.

Kwadijk-de Gijsel S, Bijl MJ, Visser LE, van Schaik RH, Hofman A, Vulto AG, van Gelder T, Ch Stricker BH. Kwadijk-de Gijsel S, et al. Among authors: bijl mj. Br J Clin Pharmacol. 2009 Aug;68(2):221-5. doi: 10.1111/j.1365-2125.2009.03448.x. Br J Clin Pharmacol. 2009. PMID: 19694742 Free PMC article.

7

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.

Ruiter R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, Coebergh JW, van Noord C, Visser LE, Stricker BH. Ruiter R, et al. Among authors: bijl mj. Pharmacogenomics. 2010 Oct;11(10):1367-75. doi: 10.2217/pgs.10.112. Pharmacogenomics. 2010. PMID: 21047200

8

Risk factors for single and multiple basal cell carcinomas.

Kiiski V, de Vries E, Flohil SC, Bijl MJ, Hofman A, Stricker BH, Nijsten T. Kiiski V, et al. Among authors: bijl mj. Arch Dermatol. 2010 Aug;146(8):848-55. doi: 10.1001/archdermatol.2010.155. Arch Dermatol. 2010. PMID: 20713815

9

Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.

Brandon EF, Bosch TM, Deenen MJ, Levink R, van der Wal E, van Meerveld JB, Bijl M, Beijnen JH, Schellens JH, Meijerman I. Brandon EF, et al. Among authors: bijl m. Toxicol Appl Pharmacol. 2006 Feb 15;211(1):1-10. doi: 10.1016/j.taap.2005.05.004. Epub 2005 Jun 21. Toxicol Appl Pharmacol. 2006. PMID: 15975613

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters